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Surgical intervention is currently the only option for an abdominal aortic aneurysm (AAA), preventing its rupture and sudden
death of a patient. Therefore, it is crucial to determine the pathogenic mechanisms of this disease for the development of
effective pharmacological therapies. Oxidative stress is said to be one of the pivotal factors in the pathogenesis of AAAs. Thus,
we aimed to evaluate the significance of nuclear factor erythroid 2-related factor 2 (Nrf2) transcriptional activity in the
development of AAA and to verify if simvastatin, administered as pre- and cotreatment, may counteract this structural
malformation. Experiments were performed on mice with inhibited transcriptional activity of Nrf2 (tKO) and wild-type (WT)
counterparts. We used a model of angiotensin II- (AngII-) induced AAA, combined with a fat-enriched diet. Mice were
administered with AngII or saline for up to 28 days via osmotic minipumps. Simvastatin administration was started 7 days
before the osmotic pump placement and then continued until the end of the experiment. We found that Nrf2 inactivation
increased the risk of development and rupture of AAA. Importantly, these effects were reversed by simvastatin in tKO mice, but
not in WT. The abrupt blood pressure rise induced by AngII was mitigated in simvastatin-treated animals regardless of the
genotype. Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue
included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-β1
mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R).
Taken together, the inhibition of Nrf2 transcriptional activity facilitates AAA formation in mice, which can be prevented by
simvastatin. It suggests that statin treatment of patients with hypercholesterolemia might have not only a beneficial effect in
terms of controlling atherosclerosis but also potential AAA prevention.
1. Introduction
An aortic aneurysm is a permanent dilatation of the aorta
with structural malformations within all three layers of the
vascular wall. It develops most frequently in the infrarenal
aorta and is called then an abdominal aortic aneurysm
(AAA). Pathophysiology of AAA formation, although still
not entirely elucidated, involves progressive upregulation of
proteolytic pathways, apoptosis of vascular smooth muscle
cells (VSMCs), oxidative stress, and inflammation, as well
as collagen deposition which compensates elastin degrada-
tion [1–3]. Most of these processes are regulated by Nrf2
(nuclear factor (erythroid-derived 2)-like 2), a stress-
responsive transcription factor, which activates the expres-
sion of cytoprotective, antioxidant, and detoxification genes
[4, 5]. Nrf2-dependent pathways were also shown to counter-
act cardiovascular disorders by the maintenance of VSMC
contractile phenotype, regulation of vascular tone, reduction
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of lipid accumulation, and macrophage influx into the media
layer as well as inhibition of vascular calcification [5], which
are all hallmarks of AAA [2, 3]. However, the significance of
Nrf2 in AAA formation has not been addressed yet.
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA) reductase, are well-known lipid-
lowering drugs, which possess potent antioxidant and anti-
inflammatory properties [6]. Throughout the years, AAA
was considered to develop on the atherosclerotic back-
ground. More recent data suggest, however, that AAA and
atherosclerosis are different disease entities, though they
share common risk factors [2]. Statins are drugs of choice
often administered to AAA patients due to the accompany-
ing hypercholesterolemia [7]. Although many studies dem-
onstrated the beneficial effect of statins on AAA growth,
the more extensive clinical trials did not confirm these find-
ings [2, 8]. Therefore, the potential use of statins in AAA is
still a matter of debate, particularly in the context of preven-
tive therapy.
Given the potential role of Nrf2 and statins in AAA
development, we investigated if abrogation of Nrf2 transcrip-
tional activity influences the AAA occurrence in mice and, if
so, whether simvastatin treatment before and during aneu-
rysm formation modulates its onset. We found that tran-
scriptional knockout of Nrf2 in mice increased the risk of
AAA formation and rupture compared to wild-type animals.
It was accompanied by high aortic inflammation and
increased activity of gelatinases. Remarkably, AAA occur-
rence in the Nrf2-defective mice was attenuated by simva-
statin administration.
2. Methods
2.1. Animals. Experiments were performed in C57BL/6J mice
with the functional Nrf2 (wild-type (WT)) or with the tran-
scriptionally inactive form of Nrf2 (transcriptional knockout
(tKO)). Mice were generated as described previously [9] and
kindly provided by Prof. Antonio Cuadrado (Universidad
Autonoma de Madrid, Spain). In these mice, a sequence cod-
ing for carboxyl amino acid residues of Nrf2 (including DNA
binding domain) was replaced by LacZ gene. It results in the
presence of fusion protein Nrf2-LacZ, consisting of remain-
ing N-terminal 301 amino acids of Nrf2 being linked to β-
gal [10]. Upon arrival at our facility, mice have been bred
to C57BL/6J every ten generations. Six-month-old male mice
of verified genotype were used (4–7 animals per group at
each time point). The genotype was verified prior to the
experiment by DNA analysis and after the experiment by
NFE2L2 mRNA assessment (Fig. S1A-B). The animals were
maintained under specific pathogen-free conditions in the
individually ventilated cages (14/10 h light/dark cycle at a
temperature of 22 ± 2°C) and were provided with a fat-
enriched diet (25% fat) and water ad libitum. All experimen-
tal procedures were approved by the Second Local Ethics
Committee for Animal Experiments in Krakow (No.
74/2016) and performed in accordance with the guidelines
from Directive 2010/63/EU of the European Parliament on
the protection of animals used for scientific purposes.
2.2. Experimental Groups. WT and tKO mice were divided
randomly into the following groups: (1) sham (saline, n = 8),
(2) angiotensin II (1000ng/kg/min) (AngII group, n = 10 or
14), (3) simvastatin (20mg/kg/day, i.g.)+saline (Sim group,
n = 12), and (4) simvastatin (20mg/kg/day, i.g.)+angiotensin
II (1000ng/kg/min) (Sim+AngII group, n = 13).
2.3. Development of Abdominal Aortic Aneurysm. Mice were
infused via osmotic minipumps (Alzet 2004) with angioten-
sin II (1000 ng/kg/min in saline; Sigma-Aldrich) or saline
(sham group) for 28 days. Osmotic pumps were placed sub-
cutaneously under isoflurane (Aerrane, Baxter; 5% v : v in
the air) anaesthesia. Simvastatin (20mg/kg/day in saline;
Sigma-Aldrich) was administrated each morning via intra-
gastric gavage (i.g.) for 7 consecutive days before the place-
ment of the osmotic pump and also during AngII infusion.
Simvastatin action was confirmed by an increase in HMG-
CoA reductase mRNA (HMGCR) [11] both in the liver and
in the abdominal aorta (Fig. S1C-D). The scheme of the
experiment is presented in Fig. S2.
The following parameters were monitored every seven
days: body weight, blood pressure (BP), aortic diameter,
and appearance by ultrasonography (USG) (Fig. S2). BP
change after osmotic pump placement was additionally mea-
sured on day 2. The mice were sacrificed on day 14 or 28 by
overdosing of carbon dioxide; the blood and aortas were col-
lected for further biochemical analysis. The aortas were
cleaned from the adjacent connective tissue and fat, photo-
graphed on a scale ruler. They were further preserved in
OCT freezing medium for histological staining or in RNAla-
ter (Sigma-Aldrich) for gene expression analysis. In this
study, all the analyses were performed on the abdominal part
of the aorta.
2.4. Blood Pressure Monitoring. All mice underwent noninva-
sive blood pressure measurement by tail-cuff plethysmogra-
phy (BP-2000 series II, Visitech Systems) which was
preceded by a period of adaptation. The measurements were
performed by one person to decrease any bias. The results
were presented as a percentage change compared to day 0
(after adaptation time and before the administration of any
drugs). This way of data presentation was chosen to plot
the impact of administered compounds better and to mini-
mise the influence of phenotypic and age-related changes
between littermates. Importantly, no difference in mean
blood pressure between genotypes was observed at day 0.
2.5. In Vivo Ultrasound Imaging of Abdominal Aorta and
Analysis. Changes in the abdominal aorta diameter were
monitored following [12], using the high-frequency ultra-
sound imaging system (Vevo 2100, FUJIFILM VisualSonics).
Two-dimensional (B-mode) imaging using a 22-55MHz
linear-array transducer (MS550D) synchronised to the elec-
trocardiographic signal was done. The animals were placed
in a supine position on a heated table under inhalation anaes-
thesia with isoflurane (1.5-2%). The abdominal cavity was
shaved, and a prewarmed ultrasound gel was applied to the
area of interest. Longitudinal images of the suprarenal and
infrarenal aorta and transverse images at the level of the
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abdominal aorta between the diaphragm and the outlet of the
left renal artery were acquired in the B-mode and M-mode to
assess the maximum cross-sectional diameter (during dias-
tole) and aortic area in real-time for each mouse at each time
point. Each animal was inspected in both B-mode and M-
mode when analysing the north-south axis (longitudinal)
and in B-mode for the west-east (transversal) axis. B-mode
images were taken between the diaphragm and the mesen-
teric artery. At the M-mode, the abdominal aorta was visua-
lised between the diaphragm and iliac arteries. The aorta was
circled using enough number of markers to reflect its shape.
To assess the aortic diameter and area, three consecutive
images of the aorta were marked. Using the software tool
for aortic diameter measurement, the beginning and the
end of the line segment were pointed, and the aortic diameter
in millimetres (mm) was measured by the software. Each
time, three line segments between the diameter and mesen-
teric arteries were analysed to provide a mean value of the
diameter. The scheme of analysis is shown in the supplemen-
tary materials (Fig. S3), given that the most reproducible
results, and burdened with the lowest error, were obtained
from M-mode measurements. Thus, results analysed this
way were included in the manuscript. Similar to blood
pressure measurements, the data is presented as the change
of day 0 in order to outline the general trend of changes
upon receiving compounds. Importantly, no difference in
the mean aortic diameter between genotypes was observed
at day 0.
2.6. Blood Cell Count. Right after euthanasia, approximately
1mL of blood was collected from retroorbital sinus to a tube
coated with EDTA. Blood cell count was analysed using an
ABC Vet Haematology Analyzer (Horiba).
2.7. Total RNA Isolation, Reverse Transcription, and
Quantitative PCR. RNA from 5mm fragment of the abdom-
inal aortic tissue was extracted with the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions.
cDNA was synthesised using a High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific). RT-qPCR was
conducted on Step-One Plus Real-Time PCR Systems using
a Power SYBR® Green PCR Master Mix according to the
manufacturer’s instructions (Thermo Fisher Scientific).
Primer sequences are gathered in Table S1. Eukaryotic
mouse translation elongation factor 2 (eEF2) was used as a
reference gene. Relative gene expression was calculated
using the ΔΔCt method.
2.8. Assessment of Redox Status of the Aorta. Detection of
reactive oxygen species (ROS) was performed with CellROX
Deep Red Reagent (Thermo Fisher Scientific) and analysed
using a meta laser scanning confocal microscope (LSM-880;
Carl Zeiss).
2.9. Histological and Immunofluorescent Analysis. Immuno-
fluorescent stainings were done in frozen 20μm (collagens I
and III, phospho-ERK), 30μm (AT1R), or 40μm (CD45,
CD64) specimens of the abdominal aorta. Elastin was stained
on 5μm tissue slices using the Verhoeff-van Gieson method
available on IHCworld protocols website. Samples were ana-
lysed under a light microscope (Nikon) with NIS elements
BR software (Canon) at magnifications of 100x and 200x.
Immunofluorescent stainings were performed on frozen
tissue slides. Samples were fixed with methanol (for AT1R
and phospho-ERK) or ice-cold acetone (for collagens I and
III and CD45/CD64) and blocked in 10% goat serum (GS)
with 0.05% Tween-20 for 1 h at room temperature (RT).
After washing in PBS, samples were incubated overnight
(4°C) with rabbit anti-AT1R polyclonal IgG antibodies (dilu-
tion 1 : 100; Abcam), rabbit anti-collagen I or collagen III IgG
polyclonal antibodies (dilution 1 : 250; Abcam), rabbit anti-
phospho-ERK1/2 IgG polyclonal antibody (dilution 1 : 100;
Cell Signaling Technology), APC-conjugated rat antibody
anti-mouse CD45 (BD, clone 30-F11), and PE-conjugated
rat antibody anti-mouse CD64 (BD, Clone X54-5/7.1)
diluted in 1% GS with 0.05% Tween-20. On the next day,
samples were washed and incubated with anti-rabbit anti-
bodies conjugated with Alexa Fluor 488 or Alexa Fluor 647
(dilution 1 : 1000; IgG H+L, Life Technologies) for 1 h at
RT. Nuclei were counterstained with Hoechst 33342
(1μg/mL, Sigma-Aldrich) during the second washing. Nega-
tive controls are presented in Fig. S7. Samples were analysed
under a fluorescent microscope (Nikon Eclipse TE 2000-U
microscope fitted with a camera) at magnifications of 100x,
200x, and 400x or a meta laser scanning confocal microscope
(LSM-880; Carl Zeiss) and analysed using ImageJ software
(Wayne-Rasband (NIH)).
2.10. In Situ Gelatin Zymography (ISZ) with MMP-9
Analysis. In situ gelatinolytic activity in the media of a frozen
abdominal aorta was performed as described previously [13].
A 1mg/mL stock solution of fluorescein-conjugated, dye-
quenched gelatin from a pig skin (DQ™-gelatin, Thermo
Fisher Scientific) was prepared in gelatinase reaction buffer
(150mM NaCl, 5mM CaCl2, 0.2mM NaN3, 50mM Tris-
HCl, pH7.6) and stored at 4°C. The working solution for
DQ-gelatin was made by directly diluting DQ-gelatin stock
solution in reaction buffer to a final concentration of
20μg/mL. Frozen, unfixed 8μm sections were thawed,
marked with PAP pen, covered with DQ-gelatin working
solution, and incubated at 37°C in a dark wet chamber for
2 h. Next, slides were washed three times in MilliQ water,
fixed for 1 minute in ice-cold acetone, washed three times
in PBS, and blocked in the wet, dark chamber with 10% GS
with 0.05% Tween-20 for 1 h at RT. Further, scraps were
overlaid with rabbit anti-mouse MMP-9 polyclonal antibod-
ies (1 : 100, Cell Signaling Technology) in 1% GS with 0.05%
Tween-20 and left overnight at 4°C in a dark wet chamber.
On the next day, samples were washed and incubated with
anti-rabbit antibodies conjugated with Alexa Fluor 568 for
collagens I and III (dilution 1 : 1000; IgG H+L, Life Technol-
ogies) for 1 h at RT. Nuclei were counterstained with Hoechst
33342 (1μg/mL, Sigma-Aldrich) during the second washing.
Samples were mounted in DAKO mounting medium and
analysed under a fluorescent microscope (Nikon Eclipse TE
2000-U microscope fitted with a camera) at magnification
100x and analysed using ImageJ software.
The specificity of the ISZ protocol was confirmed
through negative controls. Samples were preincubated for
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1h at 37°C with 1mM 1,10-phenanthroline (gelatinase activ-
ity blockage) dissolved in gelatinase reaction buffer, then
washed with PBS and incubated with the working solution
for DQ-gelatin and stained for MMP-9 as described above
(negative controls are presented in Fig. S6B). Finally, inhibi-
tion of DQ-gelatinase activity was analysed under a fluores-
cent microscope (Nikon Eclipse TE 2000-U microscope
fitted with a camera) at a magnification of 100x and analysed
using ImageJ software.
2.11. Human Abdominal Aortic Aneurysm Samples. Detailed
characteristics of patients are described in our previous
papers [14, 15]. Aneurysm wall tissue was collected during
surgery. AAA diameter was measured with preoperative
computed tomography angiography. The study was approved
by the local institutional ethics committee (EC 294/2009) at
the Medical University of Vienna.
2.12. Statistical Analysis. Data are presented as the mean ±
SEM. Three-way ANOVA, followed by Tukey’s post hoc
test, was used for the comparison of more than two groups.
Fisher’s exact test was used to calculate the frequency of
aneurysm appearance and rupture. Spearman’s test was
applied to calculate correlations. Grubbs’ test was used to
detect statistically significant outliers (p < 0:05), which were
not included in the statistical analysis of the results (Graph-
Pad Prism software). p < 0:05 was accepted as statistically
significant.
3. Results
3.1. Simvastatin Reduces the Risk of AAA Formation and
Rupture in Mice Lacking the Functional Nrf2. The classical
model of AAA induction is based on AngII infusion in ApoE
knockout (ApoE KO) mice, which lead to 70-80% aneurysm
incidence [16]. However, given the debatable role of hyper-
lipidaemia in aneurysm etiology [17, 18] and possible aggra-
vation of aneurysm formation under Nrf2 transcriptional
deficiency, we decided to use a model of AngII-induced
AAA combined with fat-enriched diet in C57BL6/J mice,
instead of the ApoE KO mice. This model provided the for-
mation of AAA in 30% of the animals (Figures 1(a) and
1(b)). In response to AngII infusion, none of the animals
exhibited a dilatation in the thoracic or ascending part of
the aorta, independently of the abdominal region. To analyse
the effect of Nrf2 transcriptional activity, we used C57BL6/J
mice with a transcriptionally inactive form of Nrf2 (Nrf2
tKO). Such mice were significantly more susceptible to aneu-
rysm formation in comparison to WT counterparts since
AngII infusion resulted in a 3-fold increase in the frequency
of AAA (Figures 1(a) and 1(b)). Moreover, AAA rupture
was observed in Nrf2 tKO animals only and occurred up to
day 6 after AngII infusion (Figure 1(c)). The AAA formation
was reduced by 80% by simvastatin in Nrf2 tKO mice
(Figures 1(a) and 1(b)), and sudden death caused by the
aneurysm rupture was also abolished (3/14 vs. 0/11 in AngII
vs. Sim+AngII groups; Figure 1(c)). No significant morpho-
logical changes were observed in the aortas of the saline- or
Sim-treated groups (Fig. S4A, B).
In contrast to WT mice, AngII infusion significantly
increased the maximal aortic diameter in Nrf2 tKO animals,
which was measured with ultrasonography (USG) at the
suprarenal region of the abdominal aorta (Figures 1(d)
and 1(e)). An initial aortic dilatation was captured on
USG in the longitudinal plane as early as day 7 in AngII-
treated Nrf2 tKO mice. Such an early dilatation was com-
monly associated with further dissection of the aorta at
day 28 (longitudinal and transverse plane; Figure 1(e)).
These effects were counteracted by simvastatin treatment
(Figures 1(d) and 1(e)).
3.2. Simvastatin Delays the AngII-Induced Blood Pressure
Rise. AngII increases systemic blood pressure, which may
lead to vascular damage. It also perpetuates inflammation
and oxidative stress, both directly associated with the forma-
tion of AAA [2, 3, 19]. Therefore, we monitored the time
course of blood pressure rise upon the AngII infusion. AngII
caused an abrupt increase in systolic blood pressure (SBP) in
mice of both genotypes within the first two days (34.5% in
WT and 40.1% in Nrf2 tKO). However, whereas in WT ani-
mals the blood pressure stabilised at day 14, in Nrf2 tKO
mice, it tended to rise until day 28. So, at the end of the exper-
iment, SBP in the AngII-treated Nrf2 tKO mice was around
45.0% higher than that in the Nrf2 tKO sham group and over
15% higher in comparison to that in AngII-treated WT mice
(Figures 2(a) and 2(b)).
Importantly, simvastatin attenuated the rise of SBP in
both genotypes on day 2. In Sim+AngII WT mice, SBP rose
gradually up to day 14 and then remained stable. In Sim
+AngII-administered Nrf2 tKO mice, SBP did not stabilise
and on day 28 was 65.0% higher compared to day 0
(Figures 2(a) and 2(b)). These effects of simvastatin referred
only to its combination with AngII. Simvastatin alone did
not influence SBP in any of the genotypes (Figures 2(a)
and 2(b)).
3.3. AAA Formation in Nrf2 tKO Mice Is Accompanied by an
Inflammatory Response. One of the mechanisms of AngII-
induced AAA development is the recruitment of monocytes
and their differentiation to the effector macrophages [3]. This
is why we assessed the inflammatory response to AngII
infusion. The analysis of the count and profile of circulating
leukocytes on day 14 revealed no differences between
inspected groups (Figure 3(a). On the other hand, in the aor-
tic tissue of Nrf2 tKO mice, AngII led to a remarkable upreg-
ulation of VCAM1 (vascular cell adhesion molecule-1) and
SELE (E-selectin) expression, genes coding for endothelial
adhesion proteins that mediate the recruitment of leukocytes
into sites of inflammation. This increase was the most pro-
nounced in the individuals which have developed the aneu-
rysms (Figure 3(b)). Of note, even in saline-treated Nrf2
tKO mice, the level of VCAM1 was significantly higher than
that in WT counterparts, implying the inflammatory state
of intact Nrf2 tKO aortas (Figure 3(b)). AngII-induced
increase in VCAM1 and SELE expression was completely
inhibited by simvastatin.
Expression of proinflammatory cytokines, such as IL1B
(known to be expressed mainly in activated macrophages),
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Figure 1: Simvastatin reduces the risk of AAA formation and rupture in Nrf2 tKO mice. Mice of both genotypes were divided into the
following groups: (1) sham (saline, n = 8), (2) angiotensin II (AngII group, n = 10 or 14), (3) simvastatin+saline (Sim group, n = 12), and
(4) simvastatin+angiotensin II (Sim+AngII group, n = 13). Simvastatin was administered daily for 7 consecutive days before osmotic
pump placement and during AngII infusion for another 28 days. (a) The frequency of aortic aneurysm appearance (Fisher’s exact test),
and (b) representative image of aortas isolated from WT and Nrf2 tKO mice. Hashtag indicates a dissected aneurysm. Scale bar = 4mm.
(c) The frequency of aneurysm rupture (Fisher’s exact test). (d) Time-dependent changes in the aortic inner diameter measured with USG.
Three-way ANOVA and Tukey’s post hoc test. (e) Representative images of aortic inner diameter changes in WT and Nrf2 tKO mice at
days 7 and 28 of AngII and Sim+AngII treatment ∗p < 0:05 and ∗∗p < 0:01 vs. saline; #p < 0:05 and ##p < 0:01 vs. AngII.
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IL6 (which can be induced in monocytes and macrophages in
response to IL1β), and IL4 (known to be expressed primarily
in lymphocytes), was detectable in the aortic tissue of both
genotypes, but not significantly affected by AngII. Simva-
statin showed a tendency to increase the expression of cyto-
kines in Nrf2 tKO aortas (Figure 3(c)). The infiltration of
CD64+/CD45+ myeloid cells into the aortic wall was present
only in those animals that have developed the aneurysms
upon AngII infusion and seemed to be more pronounced in
Nrf2 tKO mice. Simvastatin attenuated the infiltration of
myeloid cells in mice of both genotypes (Figure 3(d)).
Changes in circulating leukocyte content and expression
of endothelial adhesion molecules were all attenuated on
day 28 (Fig. S5A, B). Therefore in the next analyses, we
focused on day 14, as a selected time point.
3.4. AngII-Induced Oxidative Stress Is Not Affected by
Simvastatin.AAA aetiology strongly relies on oxidative stress
[2, 3], and Nrf2 is the essential regulator of the cellular oxida-
tive stress response [4]. Therefore, we evaluated the redox
status of aortas. The level of reactive oxygen species (ROS)
was assessed using a fluorescent probe. The comparison of
control aortas from the sham WT and Nrf2 tKO mice
revealed a modest increase in ROS in the Nrf2 tKO animals.
AngII increased the ROS production in WT aortas to the
level seen in Nrf2 tKO mice (Figure 4(a)). Importantly, in
animals that have developed AAA, the ROS level within the
aneurysmal tissue was higher, independently of the genotype.
Simvastatin did not attenuate the effect of AngII treatment,
regardless of the mouse genotype. Both in the WT and in
Nrf2 tKO animals, simvastatin alone or in combination with
AngII did not change or had a minor effect on the expression
of antioxidative genes, HMOX1 (heme oxygenase-1) and
NQO1 (NAD(P)H quinone dehydrogenase-1) (Figure 4(b)).
3.5. Simvastatin Mitigates AngII-Dependent Aortic Wall
Rearrangements. Formation of an aneurysm is strictly related
to aortic wall rearrangements [2]. Elastin Van Gieson (EVG)
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represent the following groups: (1) sham (saline, n = 4), (2) angiotensin II (AngII group, n = 5), (3) simvastatin+saline (Sim group, n = 6), and
(4) simvastatin+angiotensin II (Sim+AngII group, n = 6). Simvastatin was administered daily for 7 consecutive days before osmotic pump
placement and during AngII infusion for another 14 days. (a) Quantification of circulating white blood cells and their subpopulations
(LYM: lymphocytes; MON: monocytes; GRA: granulocytes). Three-way ANOVA with Tukey’s post hoc test. (b) Relative expression of
VCAM1 and SELE in the aortic wall. eEF2 was used as a reference gene. Three-way ANOVA with Tukey’s post hoc test. (c) Relative
expression of IL-1b, IL4, and IL6 in the aortic wall. eEF2 was used as a reference gene. Three-way ANOVA with Tukey’s post hoc test.
Rectangle—mice which developed the aneurysm. (d) Immunofluorescent staining of infiltrating CD45+ and CD64+ cells within the aortic
wall. CD45: yellow; CD64: red; nuclei: blue; L: lumen; magnification at 200x. Scale bar = 50μm. ∗p < 0:05 and ∗∗∗p < 0:001 vs. saline;
#p < 0:05 and ###p < 0:001 vs. AngII; @p < 0:05 and @@@p < 0:001 vs. WT.
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staining confirmed the appearance of elastin damage in mice
treated with AngII, regardless of genotype or aneurysm inci-
dence. The occurrence of elastin damage was partially atten-
uated by simvastatin (Figure 5(a)). AngII also promoted
collagen transcription (COL1A1, COL1A2, and COL3A1),
the effect more pronounced in Nrf2 tKOmice and intensified
in mice that have developed an aneurysm (Figure 5(b)). It
was followed by changes in immunofluorescent staining of
collagen I, but not collagen III. Simvastatin reduced the
AngII-mediated increase in COL1A1 and COL3A1 expres-
sion (Figure 5(b)), but this effect was not visible at the protein
level (Figure 5(c)).
Interestingly, a significant reduction in collagen I and III
content was observed in the aneurysmal tissue, suggesting the
enhanced protein degradation (Figure 5(c)). High collagen
degradation within the aortic wall could be explained by the
enhanced MMP (matrix metalloproteinase) activity. Hence,
we performed in situ zymography (ISZ) and costained sam-
ples for MMP9, which is known to be strongly expressed in
AAA tissue [20].
AngII increased gelatinase activity, which was attenuated
by simvastatin (Figure 6(a)). The increase was independent
of MMP9 level (Figure 6(a)), although in Nrf2 tKO mice
without aneurysms, MMP9 signal could colocalise with gela-
tinase activity, suggesting a role of MMP9 in aortic wall deg-
radation. The activity of gelatinases was the highest within
the tissue of dissecting aneurysms, but here, no colocalisation
with MMP9 was observed (Figure 6(a)). In accordance with
immunofluorescent staining, no significant changes were
observed on the MMP9 mRNA level (Fig. S6A).
In the next step, we inspected the expression of other
MMPs, MMP2 and MMP3, known to play a role in aortic
wall degradation during aneurysm formation [20]. AngII
infusion promoted the expression of both MMP2 and
MMP3, and the effect was more pronounced in Nrf2 tKO
mice. AngII-induced elevation of MMP2 and MMP3 tran-
scripts was attenuated by simvastatin (Figure 6(b)). Of note,
their pattern of expression was highly similar to the metallo-
proteinase activity (Figures 6(a) and 6(b)).
3.6. Simvastatin May Inhibit AT1R-Dependent Intracellular
Signalling. AngII regulates vascular tension and blood pres-
sure acting on its receptors (AT1R and AT2R) localised on
endothelial and smooth muscle cells and influencing inter-
cellular signalling, which plays a crucial role in aortic wall
rearrangements [19]. AngII often acts in synergy with TGFβ
[21]. We inspected the expression of TGFb1, which showed
a similar pattern of expression of MMP2 and MMP3, but
also COL1A1, COL1A2, and COL3A1 (Figures 6(c), 6(b),
and 5(b)).
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Figure 4: AngII-induced ROS level is not reduced by simvastatin. Mice of both genotypes represent the following groups: (1) sham (saline,
n = 4), (2) angiotensin II (AngII group, n = 5), (3) simvastatin+saline (Sim group, n = 6), and (4) simvastatin+angiotensin II (Sim+AngII
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ANOVA with Tukey’s post hoc test.
8 Oxidative Medicine and Cellular Longevity
W
T
tK
O
AngII (no AAA)Saline Sim+AngIISim
L
L L
L
L L
L
L
(a)
0
5
10
15
20
25
WT tKO
C
O
L
1
A
1
 (r
el
. e
xp
re
ss
io
n)
###
p = 0.12
0
5
10
15
0
5
10
15
20
C
O
L
3
A
1
 (r
el
. e
xp
re
ss
io
n)
WT tKO
# ###
p = 0.1
C
O
L
1
A
2
 (r
el
. e
xp
re
ss
io
n)
WT tKO
p = 0.08
@@ p = 0.2
Saline
Sim
AngII
Sim+AngII
⁎⁎⁎
⁎
⁎⁎⁎
⁎
(b)
W
T
tK
O
Collagen 1 Hoechst
L
L
L
L
L
L
L
L
L
L
AngII (no AAA) AngII (AAA)Saline Sim+AngIISim
(c)
W
T
tK
O
Collagen 3 Hoechst
L
L
L
L
L
L
L
L
L
L
AngII (no AAA) AngII (AAA)Saline Sim+AngIISim
(d)
Figure 5: Simvastatin mitigates AngII-induced changes in collagen and elastin status. Mice of both genotypes represent the following groups:
(1) sham (saline, n = 4), (2) angiotensin II (AngII group, n = 5), (3) simvastatin+saline (Sim group, n = 6), and (4) simvastatin+angiotensin II
(Sim+AngII group, n = 6). Simvastatin was administered daily for 7 consecutive days before osmotic pump placement and during AngII
infusion for another consecutive 14 days. (a) Verhoeff’s Van Gieson staining of abdominal aortas for elastin fibers at magnification 200x.
L: lumen. Scale bar = 25 μm; arrow—elastin breaks. (b) Relative expression of Col1α1, Col1α2, and Col3α1 within the abdominal aortic
wall. eEF2 was used as a reference gene. Three-way ANOVA with Tukey’s post hoc test. Rectangle—mice, which developed the aneurysm.
Immunofluorescent staining of (c) collagen I and (d) collagen III within the abdominal aorta at magnification 200x. L: lumen. Collagen:
red; nuclei: blue. Representative images. Scale bar = 50μm. ∗p < 0:05 and ∗∗∗p < 0:001 vs. saline; #p < 0:05 and ###p < 0:001 vs. AngII.
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Figure 6: AAA formation is associated with enhanced metalloproteinase activity. Mice of both genotypes represent the following groups: (1)
sham (saline, n = 4), (2) angiotensin II (AngII group, n = 5), (3) simvastatin+saline (Sim group, n = 6), and (4) simvastatin+angiotensin II
(Sim+AngII group, n = 6). Simvastatin was administered daily for 7 consecutive days before osmotic pump placement and during AngII
infusion for another 14 days. (a) The activity of gelatinases (green) and MMP-9 level (red) at a magnification of 100x. Blue: nuclei. The
activity of gelatinases was assessed by in situ zymography. Representative images. Scale bar = 0:1mm. L: lumen. (b) Relative expression of
MMP2 and MMP3 within the abdominal aortic wall. eEF2 was used as a reference gene. Three-way ANOVA with Tukey’s post hoc test.
Rectangle—mice, which developed the aneurysm. (c) Relative expression of TGFB1 within the abdominal aortic wall. eEF2 was used as a
reference gene. Three-way ANOVA with Tukey’s post hoc test. Rectangle—mice, which developed the aneurysm. ∗p < 0:05 and ∗∗p < 0:01
vs. saline; #p < 0:05 and ##p < 0:01 vs. AngII; @p < 0:05 vs. WT.
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The protein level of AT1R receptor remained unchanged
irrespectively of the treatment (Figure 7(a)). However, con-
sidering the role of simvastatin in the inhibition of mevalo-
nate pathways, thus influencing anchoring of signal
transducers [22], we supposed that it might inhibit intracel-
lular signalling from AT1R. We examined the activation of
W
T
tK
O
Sham
L
L
L
L
L
L
AngII (no AAA) Sim+AngIISim AngII (AAA)
AT1R Hoechst
L
L
L L
L
(a)
W
T
tK
O
AngIISaline Sim+AngIISim
P-ERK Hoechst
AngII (AAA)
L
L
L
L
L
L
L
L L
L
L
(b)
P-
p4
2/
p4
2 
ra
tio
 (a
.u
.)
AAA diameter (mm)
0.0
0.5
1.0
1.5
0 50 75 100 125
r = 0.5711
(c)
0.0
0.5
1.0
1.5
0 50 75 100 125
P-
p4
4/
p4
4 
ra
tio
 (a
.u
.)
AAA diameter (mm)
r = 0.4949
(d)
N
Q
O
1
 (r
el
. e
xp
re
ss
io
n)
AAA diameter (mm)
0
0.00
0.01
0.02
0.03
0.04
0.05
50 75 100 125
Simvastatin
No statins
r = 0.6620
r = –0.6261
(e)
Figure 7: AT1R-dependent signalling upon AngII and simvastatin treatment. Mice of both genotypes represent the following groups: (1)
sham (saline, n = 4), (2) angiotensin II (AngII group, n = 5), (3) simvastatin+saline (Sim group, n = 6), and (4) simvastatin+angiotensin II
(Sim+AngII group, n = 6). Simvastatin was administered daily for 7 consecutive days before osmotic pump placement and during AngII
infusion for another 14 days. Immunofluorescent staining of (a) AT1R and (b) P-ERK within the abdominal aortas at magnification 200x.
L: aortic lumen. Representative images. Scale bar = 50μm. Correlation of AAA diameter with (c) P-p42/p42 ratio (Spearman’s correlation
r = 0:5711, p < 0:01, n = 24) and (d) P-p44/p44 ratio (Spearman’s correlation r = 0:4949, p < 0:01, n = 24) and (e) correlation of AAA
diameter with NQO1 mRNA level among simvastatin-administered patients (black, Spearman’s correlation r = 0:6620, p < 0:001, n = 28)
and nonstatin-treated patients (red, Spearman’s correlation r = 0:−6261, p < 0:05, n = 13).
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ERK1/2, which is one of the executors of downstream signal-
ling from AT1R [19] and could partially serve as an indicator
of pathway activation. The immunofluorescent staining con-
firmed the strong activation of ERK1/2, more pronounced in
Nrf2 tKO mice infused with AngII in comparison to WT
counterparts, which was abolished when mice were adminis-
tered with simvastatin (Figure 7(b)). It might support the
supposition that the protective effect of simvastatin in the
prevention of aneurysm formation could be attributed to
inhibition of AT1R intracellular signalling.
Then, we inspected the relationship between activation of
ERK within aneurysm tissue in respect to its size, which
reflects the progression of the aneurysm and the risk of its
rupture. The characteristics of patients with AAA subjected
to the analysis were described in our previous papers [14,
15]. AAA size positively correlated with the level of activated
p42 (ERK1) (Figure 7(c), Spearman’s correlation r = 0:5711,
p < 0:01, n = 24) and activated p44 (ERK2) (Figure 7(d),
Spearman’s correlation r = 0:4949, p < 0:01, n = 24). Finally,
we correlated AAA size with the level of Nrf2 transcriptional
activity, assessed by expression of Nrf2 target gene NQO1. It
revealed a positive correlation between aneurysm size and
NQO1 level among patients administered with simvastatin
(Figure 7(e)—black, Spearman’s correlation r = 0:6620, p <
0:001, n = 28). On the contrary, among patients who did
not receive statins, Nrf2 transcriptional activity negatively
correlated with aneurysm susceptibility (Figure 7(e)—red,
Spearman’s correlation r = 0:−6261, p < 0:05, n = 13).
4. Discussion
Several studies discuss the role of Nrf2 in the regulation of
not only oxidative stress but also vascular tone and throm-
boresistance [5, 23]. The proper functioning of those pro-
cesses is crucial for the maintenance of vascular response to
microinjuries which may forerun activation of MMPs, rear-
rangement of the extracellular matrix, and damage of elastin
fibers that finally lead to the aortic stiffness, blood pressure
upregulation, aortic dilatation, and aneurysm formation [2].
Here, we report that lack of transcriptionally active form
of Nrf2 increases the risk of AAA development and rupture
in mice. This matches the previous observation that activa-
tion of Nrf2 can counteract AAA formation [5] and confirms
that Nrf2 plays a role in the prevention of AAA development.
Our group showed that the aortas of Nrf2 tKO mice undergo
premature senescence [24], which could increase the suscep-
tibility to aneurysm formation. In accordance, age-related
decline in Nrf2 transcriptional activity in human correlates
with the incidence of cardiovascular disorders, also AAA [5].
Repeatedly, the incidence of AAA is parallel to the occur-
rence of atherosclerosis. Still, debate arises if atherosclerosis
triggers the aneurysm formation. In our experimental setup,
we observed no signs of atherosclerotic plaque development
despite the consumption of a fat-enriched diet. It stays in line
with literature data, showing that during AngII infusion, ath-
erosclerotic lesions form after day 28 [25]. Still, it may sub-
stantiate that AAA formation may be independent of
atherosclerosis progression. However, lipid-lowering drugs
are prescribed to patients with an aortic aneurysm.
The role of statins in AAA prevention and treatment
remains ambiguous. Nevertheless, analogously to our exper-
iments, statin administration is protective in counteracting
aortic dilatation in Marfan syndrome [26]. Several studies
point out that the protective effects of statins depend on
Nrf2 transcriptional activity [27, 28]. However, in our exper-
imental setup, statins were protective independently of Nrf2
activation. It stays in line with our recent finding that in
response to simvastatin Nrf2 translocates to the nucleus but
does not stimulate ARE-driven transcription [14]. Accord-
ingly, our data suggest a more protective effect of statins
among patients with lower Nrf2 transcriptional activity.
However, it would require more detailed analysis.
Up to date, the universal model of aneurysm formation
has been the infusion of AngII to ApoE KO mice. However,
given the debatable role of hyperlipidaemia in aneurysm eti-
ology [17, 18] and possible aggravation of aneurysm forma-
tion under Nrf2 transcriptional deficiency, in our study, we
decided to replace ApoE KO mice with mice of normal lipid
metabolism but fed them a fat-enriched diet. By using such a
strategy, we aimed to establish an AAA model using mice,
which have been used for years. It could give us insights in
AAA formation mechanisms and relate our previous findings
to the impact on cardiovascular disorders. Aortas of Nrf2
transcriptional knockout mice undergo premature senes-
cence, exhibit massive protein S-nitrosation [24], and
enhanced protein aggregation [29] which could partially
explain the higher susceptibility to AngII-induced AAA
formation.
AngII-based models promote inflammatory response
and mobilisation of monocytes from the spleen in case of
ApoE knockout mice, which was found at the day 3 [30]. It
may explain why in our experimental setup, we did not
observe any significant changes in circulating leukocytes at
later time points. Nonetheless, the formation of the aneurysm
was associated with a higher inflammatory response, as evi-
denced by a higher VCAM1 expression and substantial mye-
loid cell infiltration. Of note, Nrf2 regulates cellular
inflammatory response [31]. The loss of Nrf2 in macro-
phages enhances foam cell formation due to increased LDL
(low-density lipoprotein) uptake and promotes the expres-
sion of the proinflammatory cytokines, e.g., MCP1, IL6, and
TNFα [32]. In our experimental model, Nrf2 transcriptional
deficiency did not affect the expression of IL1β, IL4, or IL6.
Looking for the mechanism of increased susceptibility to
aneurysm onset, we monitored the blood pressure. Literature
data indicate that Nrf2 deficiency contradicts hypertension
by interference with angiotensin II metabolism and angioten-
sin receptor expression in diabetic mice [33]. Furthermore,
Nrf2 regulates the activity of neurons that reside in the
cardiovascular centre (the rostral ventrolateral medulla
(RVLM)) by controlling the degradation of free radicals
which cause sympathoexcitation of neurons and eventually
hypertension in rodents [34]. In our study, up to day 14,
i.e., during initial aneurysm development, the time course
of changes in blood pressure was comparable between both
genotypes. Data presented by Li et al. indicate that AngII
infusion leads to a similar elevation in blood pressure in
WT and Nrf2 tKO mice leading, however, to cardiac
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hypertrophy only in the latter [35]. That is why, considering
the effect of simvastatin on AAA prevention and the fact that
it attenuates the blood hypertension, we suppose that the
abrupt blood pressure rise may lead to more severe damage
in Nrf2 tKO aortas and trigger aneurysm formation. Of note,
the hypotensive effect of statins is well documented [36],
recurrently considered a side effect of statin-based therapy.
In our experimental setup, however, it seems to have a pro-
tective outcome, possibly due to subsequent, rather than
antecedent, AngII administration.
Aneurysm formation correlates with increased oxidative
stress [2] or imbalance between key antioxidant players
[37]. Although Nrf2 is a crucial regulator of cellular response
to oxidative stress [4, 5], the inhibition of its transcriptional
activity did not lead to excessive cellular ROS production in
our animal model. It stays in agreement with our previous
data that in the aortas of Nrf2 tKO mice, there are no signs
of oxidative damage, manifested by lipid peroxidation [24].
Here, we demonstrated that irrespective of the genotype,
AngII infusion led to an increase in the ROS level, which
was partially attenuated by simvastatin treatment. Accord-
ingly, we have shown that patients who were using simva-
statin had a higher level of reduced glutathione [14].
Moreover, we observed a scarce effect on the key transcrip-
tional targets of Nrf2, NQO1, and HMOX1. It is possible that
under Nrf2 transcriptional deficiency, other transcription
factors compensate for lack of Nrf2, such as AP family mem-
bers [38]. It is also worth mentioning that Nrf2 possesses
several noncanonical functions, which reach beyond its tran-
scriptional activity. It may serve as a protein restraining
Keap1, and also in this manner, it may impact the cellular
homeostasis (reviewed in more detail in [39]).
Increased collagen turnover underlies the pathogenesis of
aneurysm [40]. Of note, our data show that simvastatin
partially mitigated changes in the aortic wall of Nrf2 tKO
mice by influencing collagen production and degradation.
We suppose that increased collagen turnover results from
the overactivity of metalloproteinases, possibly MMP2 and
MMP3, both previously reported as crucial in the aneurysm
formation [20, 41]. The pattern of expression of thoseMMPs,
especially MMP3, reflects the pattern of the gelatinase activ-
ity in the aortic wall, which could imply their role in rear-
rangement of the aortic wall and susceptibility of Nrf2 tKO
mice to AAA formation. Furthermore, statin treatment led
to the rearrangement of collagen deposition in the aortic wall.
It promoted an increase in collagen-1 in the adventitia, pos-
sibly produced by fibroblasts, which could promote vascular
integrity and protects against rupture during the increased
blood pressure [42].
The analysis of ERK1/2 activation, which may mediate
AT1R signalling, suggests that simvastatin may inhibit
AT1R signalling, which is responsible for inflammatory
response and rearrangements within the aortic wall. This
supposition is in line with our previous observations where
the reduced activity of oxidative stress-related mediators
such as NFκB and ERK1/2 as well as inhibition of MMP9
was found in AAA patients after simvastatin administration
[15, 43, 44]. Similarly, lower collagen deposition was
observed for rosuvastatin in myocardial cells [45] and for
atorvastatin in airway smooth muscle cells, where additional
downregulation of MMP9, VEGF, NFκB, and TGFβ1 was
demonstrated [46]. Going further, we confronted the results
in mice with human aneurysmal tissue, which showed that
ERK1/2 activation strongly correlates with aneurysm size
in patients. It is highly plausible that in our model based
on C57Bl/6 mice, the effect of statin was independent of
lipid-lowering action and more related to inhibition of
inflammation and intracellular AT1R signalling. However,
more detailed analyses, including assessment of lipid profile
and impact on protein modification (e.g., prenylation), are
needed to fully elucidate this point.
In conclusion, we show that lack of transcriptionally
active form of Nrf2 increases the risk of AAA development
and rupture in mice and that this process may be partially
dependent on the vascular damage caused by an enhanced
turnover of collagens and increased inflammatory response.
These effects are mitigated by simvastatin administered before
and during AngII infusion (Figure 8). Thus, it might be con-
sidered a potential prophylactic approach against AAA.
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Supplementary Materials
Supplementary Figure Legends: Fig. S1: confirmation of the
model. Mice of both genotypes were divided into the follow-
ing groups: (1) sham (saline, n = 8), (2) angiotensin II (AngII
group; n = 10 or 14), (3) simvastatin+saline (Sim group; n
= 12), and (4) simvastatin+angiotensin II (Sim+AngII
group; n = 13). Simvastatin was administered daily for 7 con-
secutive days before osmotic pump placement and during
AngII infusion for another 14 or 28 days. (A-B) Assessment
of NFE2L2 mRNA level in the abdominal aorta. (A) Relative
expression of NFE2L2 verified using primers recognizing the
fragment, encoding the DNA binding domain (exon 5). eEF2
was used as a reference gene. Three-way ANOVA with
Tukey’s post hoc test. (B) Relative expression of NFE2L2 ver-
ified using primers recognizing the fragment, encoding the N
terminal fragments of Nrf2, present in tKO mice (exon 3).
eEF2 was used as a reference gene. Three-way ANOVA with
Tukey’s post hoc test. (C, D) Verification of statin adminis-
tration through assessment of HMG-CoA reductase mRNA
level. (C) Relative expression of HMGCR in the abdominal
aorta. eEF2 was used as a reference gene. Three-way ANOVA
with Tukey’s post hoc test. (D) Relative expression of
NFE2L2 verified using primers recognizing the fragment,
encoding the N terminal fragments of Nrf2. Relative expres-
sion of HMGCR in the abdominal aorta. eEF2 was used as a
reference gene. Three-way ANOVA with Tukey’s post hoc
test. **p < 0:01 and ***p < 0:001 vs. saline; #p < 0:05 and
##p < 0:01 vs. AngII; @@@p < 0:001 vs. WT. Fig. S2: the
scheme of simvastatin and angiotensin II dosage to WT
and tKO mice together with time points of in vivo measure-
ments of blood pressure (BP) and USG. Fig. S3: the schematic
analysis of the aortic area and diameter from the B-mode (A)
and M-mode (B) for representative mice at day 0 and day 28
after osmotic pump placement. MA: the mesenteric artery;
LA: the left renal artery; RA: the right renal artery. Fig. S4:
morphological and histological changes in the aorta of WT
and tKOmice from control groups. (A) Representative image
of aortas isolated fromWT and tKO mice treated with saline
and simvastatin+saline (Sim). Scale bar = 4mm. (B) Time-
dependent changes in the aortic inner diameter (mm) of con-
trol groups measured with USG. Three-way ANOVA with
Tukey’s post hoc test. **p < 0:01 vs. saline. Fig. S5: the inflam-
matory response is attenuated at day 28. Mice of both geno-
types were divided into the following groups: (1) sham (saline
group, n = 4), (2) angiotensin II (AngII group, n = 5), (3)
simvastatin+saline (Sim group, n = 6), (4) simvastatin
+angiotensin II (Sim+AngII group, n = 7). Simvastatin was
administered daily for 7 consecutive days before osmotic
pump placement and during AngII infusion for another 28
days. (B) Relative expression of VCAM1 and SELE in the aor-
tic wall. eEF2 was used as a reference gene. Three-way
ANOVA with Tukey’s post hoc test. *p < 0:05 vs. saline. Fig.
S6: supplementary information for the assessment of metal-
loproteinase activity. (A) Relative expression of MMP9
within the abdominal aortic wall. eEF2 was used as a refer-
ence gene. Three-way ANOVA with Tukey’s post hoc test.
Rectangle—mice, which developed the aneurysm. (B) Nega-
tive controls for in situ zymography (A) performed on the
abdominal aorta in mice of both genotypes. Gelatinase activ-
ity was muted with 1 h incubation of aortic specimens with
1,10-phenanthroline (Phe, 10μM). Green-gelatinase activity,
blue-nuclei. L: lumen. Scale bar = 0:1mm. Fig. S7: negative
controls for AT1R (A) and P-ERK (B) immunofluorescent
stainings. L: lumen. Scale bar = 50 μm. Supplementary Table
1: Table 1: the sequence of primers used in the study.
(Supplementary Materials)
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